AbstractThis brief review article synthesizes the principal literature regarding the clinical status of co-trimoxazole compared to monotherapy with one of the two diami-nopyrimidines available commercially: trimethoprim or brodimoprim. Both these inhibitors of bacterial dihydrofolate reductase compare favorably to co-trimoxazole as antimicrobial chemotherapy. Brodimoprim is characterized by its advantageous pharmacokinetics in comparison to both co-trimoxazole and trimethoprim.